RadNet, Inc. (RDNT) stock
RDNTNasdaqServices-Medical LaboratoriesFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 9, 2026Score 7/3056% above fair value
$76.42+0.38 (+0.50%)
Close on Nov 13, 2026Market cap $6.01BP/E –Yield –
Earnings
RadNet's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Next report
Mar 1, 2027
Q4 FY2026 · estimated, before the open
Revenue, Q3 FY2026
$638.30M
+22.1% on a year earlier
Adjusted Diluted Earnings Per Share (3), Q3 FY2026
$0.30
$0.20 a year earlier
Latest guidance
Lowered
Nov 9, 2026 · 11 items
Quarterly results
Revenue and earnings per share from each of RadNet's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Adj. EPS | Source |
|---|---|---|---|---|---|---|
| Q4 FY2026ended Dec 31, 2026 | Mar 1, 2027Expected | – | – | – | – | – |
| Q3 FY2026ended Sep 30, 2026 | Nov 9, 2026before the open | $638.30M | +22.1% | $0.05 | $0.30 | Release |
| Q2 FY2026ended Jun 30, 2026 | Aug 10, 2026before the open | – | – | – | $0.29 | Release |
| Q1 FY2026ended Mar 31, 2026 | May 11, 2026before the open | $575.60M | +22.1% | -$0.43 | -$0.28 | Release |
| Q4 FY2025ended Dec 31, 2025 | Mar 2, 2026before the open | $547.70M | +14.8% | -$0.01 | $0.23 | Release |
| Q3 FY2025ended Sep 30, 2025 | Nov 10, 2025before the open | $522.90M | +13.4% | $0.07 | $0.20 | Release |
| Q2 FY2025ended Jun 30, 2025 | Aug 11, 2025before the open | $498.20M | +8.4% | $0.19 | $0.31 | Release |
| Q1 FY2025ended Mar 31, 2025 | May 12, 2025before the open | $471.40M | +9.2% | -$0.51 | -$0.35 | Release |
| Q4 FY2024ended Dec 31, 2024 | Mar 5, 2025during market hours | $477.10M | +13.5% | $0.07 | $0.22 | Release |
| Q3 FY2024ended Sep 30, 2024 | Nov 12, 2024during market hours | $461.10M | +14.7% | $0.04 | $0.18 | Release |
| Q2 FY2024ended Jun 30, 2024 | Aug 9, 2024during market hours | $459.70M | +13.9% | -$0.04 | $0.16 | Release |
| Q1 FY2024ended Mar 31, 2024 | May 13, 2024during market hours | $431.70M | +10.5% | -$0.04 | $0.07 | Release |
| Q4 FY2023ended Dec 31, 2023 | Mar 5, 2024before the open | $420.40M | +9.5% | -$0.03 | $0.20 | Release |
| Q3 FY2023ended Sep 30, 2023 | Nov 13, 2023before the open | $402.00M | +14.9% | $0.25 | $0.14 | Release |
| Q2 FY2023ended Jun 30, 2023 | Aug 9, 2023before the open | $403.70M | +13.9% | $0.12 | $0.24 | Release |
| Q1 FY2023ended Mar 31, 2023 | May 11, 2023during market hours | $390.60M | +14.3% | -$0.36 | -$0.08 | Release |
| Q4 FY2022ended Dec 31, 2022 | Mar 1, 2023during market hours | $383.90M | +15.2% | -$0.02 | $0.11 | Release |
| Q3 FY2022ended Sep 30, 2022 | Nov 9, 2022during market hours | $350.00M | +5.2% | $0.01 | $0.09 | Release |
| Q2 FY2022ended Jun 30, 2022 | Aug 10, 2022during market hours | $354.40M | – | $0.13 | $0.15 | Release |
| Q1 FY2022ended Mar 31, 2022 | May 10, 2022during market hours | $341.80M | – | $0.05 | -$0.15 | Release |
| Q4 FY2021ended Dec 31, 2021 | Mar 2, 2022during market hours | $333.20M | – | -$0.07 | $0.13 | Release |
| Q3 FY2021ended Sep 30, 2021 | Nov 9, 2021during market hours | $332.70M | – | $0.30 | $0.21 | Release |
| Q2 FY2021ended Jun 30, 2021 | Aug 10, 2021after the close | – | – | – | – | Filing |
| Q1 FY2021ended Mar 31, 2021 | May 11, 2021after the close | – | – | – | – | Filing |
| Q4 FY2020ended Dec 31, 2020 | Mar 9, 2021during market hours | – | – | – | – | Filing |
| Q3 FY2020ended Sep 30, 2020 | Nov 10, 2020after the close | – | – | – | – | Filing |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Current guidance
RadNet's latest outlook for periods it has not reported yet, compared with what it said before
| Metric | Period | Guidance | Before | Change | Given |
|---|---|---|---|---|---|
| Imaging Center segment Revenue growth | FY2026 | +17% – +19% | – | New | Mar 2, 2026 |
| Total Net RevenueGAAP | FY2026 | $2.39B – $2.44B | – | New | Nov 9, 2026 |
| Total Net Revenue - Digital Health Segment | FY2026 | $135.00M – $145.00M | $2.33B – $2.38B | Reaffirmed | May 11, 2026 |
| Adjusted EBITDA (1)non-GAAP | FY2026 | $350.00M – $363.00M | – | New | Nov 9, 2026 |
| Adjusted EBITDA (1) growthnon-GAAP | FY2026 | +18% – +22% | – | New | Mar 2, 2026 |
| Adjusted EBITDA Before Non-Capitalized R&D - DeepHealth Cloud OS & Generative AI - Digital Health Segmentnon-GAAP | FY2026 | $10.00M – $12.00M | $335.00M – $348.00M | Reaffirmed | May 11, 2026 |
| Free Cash Flow (2)non-GAAP | FY2026 | $120.00M – $130.00M | – | New | Nov 9, 2026 |
| Free Cash Flow (2) growthnon-GAAP | FY2026 | +29% – +41% | – | New | Mar 2, 2026 |
| Free Cash Flow Before Non-Capitalized R&D - DeepHealth Cloud OS & Generative AI - Digital Health Segmentnon-GAAP | FY2026 | -$1.00M – $3.00M | $105.00M – $115.00M | Raised | May 11, 2026 |
| Capital Expenditures - Imaging Center Segment | FY2026 | $165.00M – $175.00M | $165.00M – $175.00M | Raised | May 11, 2026 |
| Capital Expenditures (a) | FY2026 | $170.00M – $180.00M | – | New | Nov 9, 2026 |
| Cash Interest Expense - Imaging Center Segment | FY2026 | $45.00M – $50.00M | – | Raised | May 11, 2026 |
| Cash Interest Expense (b) | FY2026 | $48.00M – $53.00M | – | New | Nov 9, 2026 |
| Cash Interest Expense (b) | FY2026 | $45.00M – $50.00M | – | New | Mar 2, 2026 |
| Non-Capitalized R&D | FY2026 | $17.00M – $19.00M | – | Lowered | Mar 2, 2026 |
| Non-Capitalized R&D - DeepHealth Cloud OS & Generative AI | FY2026 | $17.00M – $19.00M | – | Lowered | Nov 9, 2026 |
| Non-Capitalized R&D - DeepHealth Cloud OS & Generative AI - Digital Health Segment | FY2026 | $17.00M – $19.00M | – | Lowered | May 11, 2026 |
Guidance vs results
The last range RadNet gave before each report, against the figure it then reported. Full years add up the four quarters.
| Period | Metric | Guidance | Actual | Result |
|---|---|---|---|---|
| FY2025 | Revenue | $1.90B – $1.93B | $2.04BΣ4Q | Above range |
Guidance history
Every forecast RadNet put in an earnings release, newest first
| Given | Metric | Period | Guidance | Change |
|---|---|---|---|---|
| Nov 9, 2026 | Capital Expenditures (a) | FY2026 | $170.00M – $180.00M | New |
| Nov 9, 2026 | Capital Expenditures | FY2026 | $10.00M – $13.00M | Lowered |
| Nov 9, 2026 | Adjusted EBITDA (1) | FY2026 | $350.00M – $363.00M | New |
| Nov 9, 2026 | Adjusted EBITDA (1) Before Non-Capitalized R&D - DeepHealth Cloud OS & Generative AI | FY2026 | $11.00M – $13.00M | Lowered |
| Nov 9, 2026 | Free Cash Flow (2) | FY2026 | $120.00M – $130.00M | New |
| Nov 9, 2026 | Free Cash Flow (2) Before Non-Capitalized R&D - DeepHealth Cloud OS & Generative AI | FY2026 | -$1.00M – $3.00M | Lowered |
| Nov 9, 2026 | Free Cash Flow (2) After Non-Capitalized R&D - DeepHealth Cloud OS & Generative AI | FY2026 | -$19.00M – -$17.00M | Lowered |
| Nov 9, 2026 | Cash Interest Expense (b) | FY2026 | $48.00M – $53.00M | New |
| Nov 9, 2026 | Non-Capitalized R&D - DeepHealth Cloud OS & Generative AI | FY2026 | $17.00M – $19.00M | Lowered |
| Nov 9, 2026 | Total Net Revenue | FY2026 | $2.39B – $2.44B | New |
| Nov 9, 2026 | Total Net Revenue (inclusive of intersegment revenue) | FY2026 | $135.00M – $145.00M | Lowered |
| May 11, 2026 | Capital Expenditures - Imaging Center Segment | FY2026 | $165.00M – $175.00M | Raised |
| May 11, 2026 | Capital Expenditures - Digital Health Segment | FY2026 | $9.00M – $12.00M | Lowered |
| May 11, 2026 | Adjusted EBITDA Before Non-Capitalized R&D - DeepHealth Cloud OS & Generative AI - Digital Health Segment | FY2026 | $10.00M – $12.00M | Reaffirmed |
| May 11, 2026 | Free Cash Flow Before Non-Capitalized R&D - DeepHealth Cloud OS & Generative AI - Digital Health Segment | FY2026 | -$1.00M – $3.00M | Raised |
| May 11, 2026 | Free Cash Flow After Non-Capitalized R&D - DeepHealth Cloud OS & Generative AI - Digital Health Segment | FY2026 | -$19.00M – -$17.00M | Lowered |
| May 11, 2026 | Cash Interest Expense - Imaging Center Segment | FY2026 | $45.00M – $50.00M | Raised |
| May 11, 2026 | Non-Capitalized R&D - DeepHealth Cloud OS & Generative AI - Digital Health Segment | FY2026 | $17.00M – $19.00M | Lowered |
| May 11, 2026 | Total Net Revenue - Digital Health Segment | FY2026 | $135.00M – $145.00M | Reaffirmed |
| Mar 2, 2026 | Capital Expenditures (a) | FY2026 | $165.00M – $175.00M | New |
| Mar 2, 2026 | Capital Expenditures | FY2026 | $9.00M – $12.00M | Lowered |
| Mar 2, 2026 | Adjusted EBITDA (1) growth | FY2026 | +18% – +22% | New |
| Mar 2, 2026 | Adjusted EBITDA (1) | FY2026 | $335.00M – $348.00M | New |
| Mar 2, 2026 | Adjusted EBITDA (1) Before Non-Capitalized R&D (b) | FY2026 | $10.00M – $12.00M | Lowered |
| Mar 2, 2026 | Free Cash Flow (2) growth | FY2026 | +29% – +41% | New |
| Mar 2, 2026 | Free Cash Flow (2) | FY2026 | $105.00M – $115.00M | New |
| Mar 2, 2026 | Free Cash Flow (2) Before Non-Capitalized R&D - DeepHealth Cloud OS & Generative AI | FY2026 | -$1.00M – $3.00M | Lowered |
| Mar 2, 2026 | Free Cash Flow (2) After Non-Capitalized R&D - DeepHealth Cloud OS & Generative AI | FY2026 | -$19.00M – -$17.00M | Lowered |
| Mar 2, 2026 | Cash Interest Expense (b) | FY2026 | $45.00M – $50.00M | New |
| Mar 2, 2026 | Non-Capitalized R&D | FY2026 | $17.00M – $19.00M | Lowered |
| Mar 2, 2026 | Imaging Center segment Revenue growth | FY2026 | +17% – +19% | New |
| Mar 2, 2026 | Digital Health Revenue growth | FY2026 | +46% – +56% | Raised |
| Mar 2, 2026 | Total Net Revenue | FY2026 | $2.33B – $2.38B | New |
| Mar 2, 2026 | Total Net Revenue (a) | FY2026 | $135.00M – $145.00M | Lowered |
| Nov 10, 2025 | Capital Expenditures (a) | FY2025 | $157.00M – $167.00M | New |
| Nov 10, 2025 | Capital Expenditures | FY2025 | $3.00M – $5.00M | Lowered |
| Nov 10, 2025 | Adjusted EBITDA (1) | FY2025 | $276.00M – $284.00M | New |
| Nov 10, 2025 | Adjusted EBITDA (1) Before Non-Capitalized R&D - DeepHealth Cloud OS & Generative AI | FY2025 | $15.00M – $17.00M | Lowered |
| Nov 10, 2025 | Free Cash Flow (2) | FY2025 | $70.00M – $80.00M | New |
| Nov 10, 2025 | Free Cash Flow (2) Before Non-Capitalized R&D - DeepHealth Cloud OS & Generative AI | FY2025 | $10.00M – $12.00M | Lowered |
| Nov 10, 2025 | Free Cash Flow (2) After Non-Capitalized R&D - DeepHealth Cloud OS & Generative AI | FY2025 | -$9.00M – -$6.00M | Lowered |
| Nov 10, 2025 | Cash Interest Expense (b) | FY2025 | $31.00M – $36.00M | New |
| Nov 10, 2025 | Non-Capitalized R&D - DeepHealth Cloud OS & Generative AI | FY2025 | $18.00M – $20.00M | Lowered |
| Nov 10, 2025 | Total Net Revenue | FY2025 | $1.90B – $1.93B | New |
| Nov 10, 2025 | Total Net Revenue (inclusive of intersegment revenue) | FY2025 | $85.00M – $95.00M | Lowered |
| Aug 11, 2025 | Capital Expenditures (a) | FY2025 | $152.00M – $162.00M | Raised |
| Aug 11, 2025 | Capital Expenditures | FY2025 | $2.00M – $4.00M | Lowered |
| Aug 11, 2025 | Adjusted EBITDA (1) | FY2025 | $271.00M – $279.00M | Raised |
| Aug 11, 2025 | Adjusted EBITDA (1) Before Non-Capitalized R&D - DeepHealth Cloud OS & Generative AI | FY2025 | $15.00M – $17.00M | Lowered |
| Aug 11, 2025 | Free Cash Flow (2) | FY2025 | $70.00M – $80.00M | Raised |
| Aug 11, 2025 | Free Cash Flow (2) Before Non-Capitalized R&D - DeepHealth Cloud OS & Generative AI | FY2025 | $11.00M – $13.00M | Lowered |
| Aug 11, 2025 | Free Cash Flow (2) After Non-Capitalized R&D - DeepHealth Cloud OS & Generative AI | FY2025 | -$8.00M – -$5.00M | Lowered |
| Aug 11, 2025 | Cash Interest Expense (b) | FY2025 | $35.00M – $40.00M | Raised |
| Aug 11, 2025 | Non-Capitalized R&D - DeepHealth Cloud OS & Generative AI | FY2025 | $17.00M – $19.00M | Lowered |
| Aug 11, 2025 | Total Net Revenue | FY2025 | $1.85B – $1.90B | Raised |
| Aug 11, 2025 | Total Net Revenue (inclusive of intersegment revenue) | FY2025 | $80.00M – $90.00M | Lowered |
| May 12, 2025 | Capital Expenditures (a) | FY2025 | $145.00M – $155.00M | New |
| May 12, 2025 | Capital Expenditures | FY2025 | $3.00M – $5.00M | Lowered |
| May 12, 2025 | Adjusted EBITDA (1) | FY2025 | $268.00M – $276.00M | Raised |
| May 12, 2025 | Adjusted EBITDA (1) Before Non-Capitalized R&D - DeepHealth Cloud OS & Generative AI | FY2025 | $15.00M – $17.00M | Lowered |
| May 12, 2025 | Free Cash Flow (2) | FY2025 | $70.00M – $80.00M | Raised |
| May 12, 2025 | Free Cash Flow (2) Before Non-Capitalized R&D - DeepHealth Cloud OS & Generative AI | FY2025 | $11.00M – $13.00M | Lowered |
| May 12, 2025 | Free Cash Flow (2) After Non-Capitalized R&D - DeepHealth Cloud OS & Generative AI | FY2025 | -$8.00M – -$5.00M | Lowered |
| May 12, 2025 | Cash Interest Expense (b) | FY2025 | $35.00M – $40.00M | New |
| May 12, 2025 | Non-Capitalized R&D - DeepHealth Cloud OS & Generative AI | FY2025 | $16.00M – $18.00M | Lowered |
| May 12, 2025 | Total Net Revenue | FY2025 | $1.84B – $1.89B | New |
| May 12, 2025 | Total Net Revenue | FY2025 | $80.00M – $90.00M | Lowered |
| Mar 5, 2025 | Capital Expenditures | FY2025 | $3.00M – $5.00M | Lowered |
| Mar 5, 2025 | Capital Expenditures (a) | FY2025 | $140.00M – $150.00M | New |
| Mar 5, 2025 | Adjusted EBITDA (1) Before Non-Capitalized R&D - DeepHealth Cloud OS & Generative AI | FY2025 | $15.00M – $17.00M | Lowered |
| Mar 5, 2025 | Adjusted EBITDA (1) | FY2025 | $265.00M – $273.00M | New |
| Mar 5, 2025 | Free Cash Flow (2) Before Non-Capitalized R&D - DeepHealth Cloud OS & Generative AI | FY2025 | $11.00M – $13.00M | Lowered |
| Mar 5, 2025 | Free Cash Flow (2) After Non-Capitalized R&D - DeepHealth Cloud OS & Generative AI | FY2025 | -$8.00M – -$5.00M | Lowered |
| Mar 5, 2025 | Free Cash Flow (2) | FY2025 | $70.00M – $80.00M | New |
| Mar 5, 2025 | Cash Interest Expense (b) | FY2025 | $35.00M – $40.00M | New |
| Mar 5, 2025 | Non-Capitalized R&D - DeepHealth Cloud OS & Generative AI | FY2025 | $16.00M – $18.00M | Lowered |
| Mar 5, 2025 | Total Net Revenue | FY2025 | $80.00M – $90.00M | Lowered |
| Mar 5, 2025 | Total Net Revenue | FY2025 | $1.83B – $1.88B | New |
| Nov 12, 2024 | Capital Expenditures (i) | FY2024 | $3.00M – $5.00M | Lowered |
| Nov 12, 2024 | Capital Expenditures (a) | FY2024 | $145.00M – $155.00M | Raised |
| Nov 12, 2024 | Adjusted EBITDA (1) Before Non-Capitalized R&D - DeepHealth Cloud OS & Generative AI | FY2024 | $13.00M – $15.00M | Lowered |
| Nov 12, 2024 | Adjusted EBITDA (1) | FY2024 | $262.00M – $270.00M | Raised |
| Nov 12, 2024 | Free Cash Flow (2) Before Non-Capitalized R&D - DeepHealth Cloud OS & Generative AI | FY2024 | $8.00M – $10.00M | Lowered |
| Nov 12, 2024 | Free Cash Flow (2) | FY2024 | $83.00M – $93.00M | Raised |
| Nov 12, 2024 | Free Cash Flow (2) After Non-Capitalized R&D - DeepHealth Cloud OS & Generative AI | FY2024 | -$5.00M – -$2.00M | Lowered |
| Nov 12, 2024 | Cash Interest Expense (b) | FY2024 | $25.00M – $30.00M | Lowered |
| Nov 12, 2024 | Non-Capitalized R&D - DeepHealth Cloud OS & Generative AI | FY2024 | $13.00M – $15.00M | Lowered |
| Nov 12, 2024 | Total Net Revenue (inclusive of intersegment revenue) | FY2024 | $60.00M – $70.00M | Lowered |
| Nov 12, 2024 | Total Net Revenue | FY2024 | $1.71B – $1.76B | Raised |
| Aug 9, 2024 | Capital Expenditures (a) | FY2024 | $135.00M – $145.00M | Raised |
| Aug 9, 2024 | Adjusted EBITDA (1) | FY2024 | $257.00M – $267.00M | Raised |
| Aug 9, 2024 | Free Cash Flow (2) | FY2024 | $72.00M – $80.00M | Raised |
| Aug 9, 2024 | Cash Interest Expense (b) | FY2024 | $32.00M – $37.00M | Raised |
| Aug 9, 2024 | Total Net Revenue | FY2024 | $1.69B – $1.74B | Raised |
| May 10, 2024 | Capital Expenditures | FY2024 | $3.00M – $5.00M | Lowered |
| May 10, 2024 | Capital Expenditures (a) | FY2024 | $130.00M – $140.00M | Raised |
| May 10, 2024 | Adjusted EBITDA (1) | FY2024 | $255.00M – $265.00M | Raised |
| May 10, 2024 | Adjusted EBITDA (1) Before Non-Capitalized R&D - DeepHealth Cloud OS & Generative AI | FY2024 | $13.00M – $15.00M | Lowered |
| May 10, 2024 | Free Cash Flow (2) After Non-Capitalized R&D - DeepHealth Cloud OS & Generative AI | FY2024 | -$5.00M – -$2.00M | Lowered |
| May 10, 2024 | Free Cash Flow (2) | FY2024 | $68.00M – $78.00M | Raised |
| May 10, 2024 | Free Cash Flow (2) Before Non-Capitalized R&D - DeepHealth Cloud OS & Generative AI | FY2024 | $8.00M – $10.00M | Lowered |
| May 10, 2024 | Cash Interest Expense (b) | FY2024 | $37.00M – $42.00M | Raised |
| May 10, 2024 | Non-Capitalized R&D - DeepHealth Cloud OS & Generative AI | FY2024 | $12.00M – $14.00M | Lowered |
| May 10, 2024 | Total Net Revenue | FY2024 | $1.68B – $1.73B | New |
| May 10, 2024 | Total Net Revenue | FY2024 | $60.00M – $70.00M | Lowered |
| Mar 5, 2024 | Capital Expenditures (a) | FY2024 | $125.00M – $135.00M | New |
| Mar 5, 2024 | Capital Expenditures | FY2024 | $3.00M – $5.00M | Lowered |
| Mar 5, 2024 | Adjusted EBITDA (1) Before Non-Capitalized R&D - DeepHealth Cloud OS & Generative AI | FY2024 | $12.00M – $14.00M | Lowered |
| Mar 5, 2024 | Adjusted EBITDA (1) | FY2024 | $250.00M – $260.00M | New |
| Mar 5, 2024 | Free Cash Flow (b) | FY2024 | $65.00M – $75.00M | New |
| Mar 5, 2024 | Free Cash Flow (a) After Non-Capitalized R&D - DeepHealth Cloud OS & Generative AI | FY2024 | -$5.00M – -$2.00M | Lowered |
| Mar 5, 2024 | Free Cash Flow (a) Before Non-Capitalized R&D - DeepHealth Cloud OS & Generative AI | FY2024 | $8.00M – $10.00M | Lowered |
| Mar 5, 2024 | Non-Capitalized R&D - DeepHealth Cloud OS & Generative AI | FY2024 | $11.00M – $13.00M | Lowered |
| Mar 5, 2024 | Cash Interest Expense (c) | FY2024 | $40.00M – $45.00M | New |
| Mar 5, 2024 | Total Net Revenue | FY2024 | $60.00M – $70.00M | Lowered |
| Mar 5, 2024 | Total Net Revenue | FY2024 | $1.65B – $1.70B | New |
| Nov 13, 2023 | Capital Expenditures (a) | FY2023 | $115.00M – $125.00M | Raised |
| Nov 13, 2023 | Adjusted EBITDA (1) | FY2023 | $235.00M – $245.00M | Raised |
| Nov 13, 2023 | Free Cash Flow (b)(2) | FY2023 | $65.00M – $75.00M | Raised |
| Nov 13, 2023 | Cash Interest Expense (c) | FY2023 | $45.00M – $50.00M | Reaffirmed |
| Nov 13, 2023 | Total Net Revenue | FY2023 | $1.58B – $1.61B | Raised |
| Aug 9, 2023 | Capital Expenditures (a) | FY2023 | $110.00M – $120.00M | Raised |
| Aug 9, 2023 | Adjusted EBITDA (1) | FY2023 | $232.00M – $242.00M | Raised |
| Aug 9, 2023 | Adjusted EBITDA (1) | FY2023 | -$13.00M – -$11.00M | Lowered |
| Aug 9, 2023 | Free Cash Flow (b)(2) | FY2023 | $65.00M – $70.00M | Reaffirmed |
| Aug 9, 2023 | Cash Interest Expense (c) | FY2023 | $45.00M – $50.00M | Raised |
| Aug 9, 2023 | Total Net Revenue | FY2023 | $11.00M – $13.00M | Lowered |
| Aug 9, 2023 | Total Net Revenue | FY2023 | $1.58B – $1.61B | Raised |
| May 10, 2023 | Capital Expenditures | FY2023 | $110.00M – $120.00M | New |
| May 10, 2023 | Adjusted EBITDA | FY2023 | $225.00M – $235.00M | Raised |
| May 10, 2023 | Free Cash Flow Generation | FY2023 | $65.00M – $70.00M | Lowered |
| May 10, 2023 | Cash Paid for Interest | FY2023 | $45.00M – $50.00M | New |
| May 10, 2023 | Revenue | FY2023 | $1.55B – $1.60B | New |
| Mar 1, 2023 | Capital Expenditures (a) | FY2023 | $105.00M – $115.00M | New |
| Mar 1, 2023 | Adjusted EBITDA (1) | FY2023 | $220.00M – $230.00M | New |
| Mar 1, 2023 | Free Cash Flow Generation (b)(2) | FY2023 | $70.00M – $80.00M | New |
| Mar 1, 2023 | Cash Paid for Interest (c) | FY2023 | $35.00M – $40.00M | New |
| Mar 1, 2023 | Revenue | FY2023 | $1.53B – $1.58B | New |
| Nov 9, 2022 | Capital Expenditures (a) | FY2022 | $100.00M – $105.00M | Raised |
| Nov 9, 2022 | Adjusted EBITDA (1) Excluding Losses from AI Segment | FY2022 | $203.00M – $208.00M | Lowered |
| Nov 9, 2022 | Free Cash Flow (b)(2) | FY2022 | $60.00M – $70.00M | Lowered |
| Nov 9, 2022 | Cash Interest Expense (c) | FY2022 | $35.00M – $40.00M | Raised |
| Nov 9, 2022 | Revenue – Imaging Ctr Operations | FY2022 | $1.36B – $1.41B | Reaffirmed |
| Aug 10, 2022 | Capital Expenditures (a) | FY2022 | $90.00M – $95.00M | Raised |
| Aug 10, 2022 | Adjusted EBITDA (1) | FY2022 | $208.00M – $218.00M | Reaffirmed |
| Aug 10, 2022 | Free Cash Flow (b)(2) | FY2022 | $80.00M – $90.00M | Reaffirmed |
| Aug 10, 2022 | Cash Interest Expense (c) | FY2022 | $27.00M – $32.00M | Reaffirmed |
| Aug 10, 2022 | Total Net Revenue | FY2022 | $1.36B – $1.41B | Raised |
| May 9, 2022 | Capital Expenditures (a) | FY2022 | $88.00M – $93.00M | Raised |
| May 9, 2022 | Adjusted EBITDA (1) Excluding Losses from Artificial Intelligence Segment | FY2022 | $208.00M – $218.00M | Raised |
| May 9, 2022 | Free Cash Flow (b)(2) | FY2022 | $80.00M – $90.00M | Reaffirmed |
| May 9, 2022 | Cash Paid for Interest (c) | FY2022 | $27.00M – $32.00M | Reaffirmed |
| May 9, 2022 | Revenue – Imaging Ctr Operations | FY2022 | $1.36B – $1.41B | New |
| Mar 2, 2022 | Capital Expenditures (a) | FY2022 | $85.00M – $90.00M | New |
| Mar 2, 2022 | Adjusted EBITDA (1) Excluding Anticipated Losses from Artificial Intelligence Businesses | FY2022 | $205.00M – $215.00M | New |
| Mar 2, 2022 | Free Cash Flow Generation (b)(2) | FY2022 | $80.00M – $90.00M | New |
| Mar 2, 2022 | Cash Paid for Interest (c) | FY2022 | $27.00M – $32.00M | New |
| Mar 2, 2022 | Total Net Revenue | FY2022 | $1.35B – $1.40B | New |
| Nov 9, 2021 | Capital Expenditures (a) | FY2021 | $85.00M – $90.00M | New |
| Nov 9, 2021 | Adjusted EBITDA (1) | FY2021 | $210.00M – $220.00M | New |
| Nov 9, 2021 | Free Cash Flow (b)(2) | FY2021 | $80.00M – $90.00M | New |
| Nov 9, 2021 | Cash Interest Expense | FY2021 | $35.00M – $40.00M | New |
| Nov 9, 2021 | Total Net Revenue | FY2021 | $1.30B – $1.35B | New |
Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.
Press releases
Releases RadNet filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Update
- Results
- Update
- News
- Results
- Results
- Update
- Update
- Results
- Results
- Update
- Update
- Results
- Update
See a number that looks wrong?